Browse by author
Lookup NU author(s): Professor Alan Boddy,
Professor Ruth Plummer,
Dr Mark Verrill
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and toxicities associated with administration of paclitaxel poliglumex (PPX, XYOTAX, Cell Therapeutics, Inc., Bresso, Italy) given on either 3-weekly or 2-weekly schedule. Experimental Design: Nineteen patients were investigated on the 3-weekly phase la study and 11 patients on the 2-weekly phase lb study. Dose escalation starting with 100% increments and one patient per dose level was modulated in accordance with the observed toxicities. Conjugated and unconjugated paclitaxel were measured in plasma. Results: Dose-limiting toxicity of neutropenia was encountered at 266 mg/m2 (paclitaxel equivalents) in phase la and the maximum tolerated dose was 233 mg/m2. Neuropathy was dose-limiting in phase lb with a maximum tolerated dose of 177 mg/m 2. Pharmacokinetic investigations indicated a prolonged half-life of >100 hours for conjugated taxanes. Plasma concentrations of unconjugated paclitaxel were similar to those following administration of an equivalent dose of Taxol. Two partial responses were observed, one in a patient with mesothelioma at 177 mg/m2 in phase la and one in a patient with gastric carcinoma at 175 mg/m2 in phase lb. Conclusion: PPX is a water-soluble paclitaxel-polymer conjugate with a prolonged half-life and limited volume of distribution. Dose-limiting toxicities were neutropenia and neuropathy. PPX showed activity in this patient population. © 2005 American Association for Cancer Research.
Author(s): Boddy AV, Plummer ER, Todd R, Sludden J, Griffin MJ, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH
Publication type: Article
Publication status: Published
Journal: Clinical Cancer Research
Print publication date: 01/11/2005
ISSN (print): 1078-0432
ISSN (electronic): 1557-3265
PubMed id: 16278406
Altmetrics provided by Altmetric